Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer’ Reveals Results For Four Lung Cancer Trials
For c-Met study, among 19 NSCLC patients who had an EML4-ALK mutation treated with PF-02341066, 10 have had a partial response, with three unconfirmed; the duration of response
For c-Met study, among 19 NSCLC patients who had an EML4-ALK mutation treated with PF-02341066, 10 have had a partial response, with three unconfirmed; the duration of response
Results from the study showed that after initial treatment with Avastin and chemotherapy, combined maintenance treatment with Avastin and Tarceva extends the time patients live without their disease
During the clinical trial, 151 blood samples were analyzed from 42 patients enrolled in the randomized Phase II study of figitumumab in combination with carboplatin and paclitaxel in
The median overall survival in patients with advanced metastatic prostate cancer, who were treated with OGX-011 plus docetaxel in a randomized phase II trial, was 23.8 months compared
In this single arm phase II study, 22 patients with newly diagnosed and optimally resected EGFRvIII-positive GBM received CDX-110 in combination with maintenance temozolomide after having completed chemoradiation
This is a quantum leap forward in terms of accuracy with timeframes that were previously unimaginable, says Sophie Wetherall, Varian BrachyTherapy software product manager. BrachyVision Acuros offers an
The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients. Ron Bentsur, CEO of Keryx, said: We
The company incurred a loss of $168197 in the first quarter of 2009, compared to $74067 for the same period in 2008. Management expects that greater sales of
According to IMS Health, Mylan has currently 117 ANDAs pending FDA approval, representing $82.1 billion in annual brand sales. Moreover, IMS also said that 35 of these pending
This follows the notification to AstraZeneca by the Netherlands Health Authority (MEB), acting as the Reference Member State for the Mutual Recognition Process (MRP), that the Seroquel XR